The dream of a vaccine against tuberculosis; new vaccines improving or replacing BCG?

European Respiratory Journal

Volumn 26, Issue 1, 2005, Pages 162-167

  Martín, Carlos ^a  

^a NONE   (Spain)

Author keywords

Live vaccines; New vaccines; Pre clinical and clinical trials; Tuberculosis

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL ANTIGEN 85A; BACTERIAL ANTIGEN 85B; BACTERIAL PROTEIN; BACTERIAL PROTEIN 72F; BCG VACCINE; DNA VACCINE; EARLY SECRETORY ANTIGENIC TARGET 6; HYBRID PROTEIN; LIVE VACCINE; NEW DRUG; POLYPROTEIN; RECOMBINANT VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; BACTERIAL IMMUNITY; BCG VACCINATION; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; EXPERIMENTAL INFECTION; FEASIBILITY STUDY; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RESISTANCE; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM;

BCG VACCINE; COMMUNICABLE DISEASE CONTROL; DRUG DESIGN; FEMALE; FORECASTING; HUMANS; INCIDENCE; MALE; RESEARCH; RISK ASSESSMENT; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINATION; WORLD HEALTH;

EID: 21744455598     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.05.00109904     Document Type: Article

References (38)

1. Espinal MA, Laszlo A, Simonsen L, et al. Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 2001; 344: 1294-1306.
2. Toossi Z, Mayanja-Kizza H, Hirsch CS, et al. Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients. Clin Exp Immunol 2001; 123: 233-238.
3. World Health Organization. W. H. O. statement on BCG revaccination for the prevention of tuberculosis. Bull W H O 1995; 73: 805-806.
4. World Health Organization. Joint statement. Consultation on human immunodeficiency virus (HIV) and routine childhood immunization. Wkly Epidemiol Rec 1987; 62: 297-299.
5. Aronson NE, Santosham M, Comstock GW, et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study. JAMA 2004; 291: 2086-2091.
6. Waddell RD, Lishimpi K, von Reyn CF, et al. Bacteremia due to Mycobacterium tuberculosis or M. bovis, Bacille Calmette-Guerin (BCG) among HIV-positive children and adults in Zambia. AIDS 2001; 15: 55-60.
7. Black GF, Weir RE, Floyd S, et al. BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet 2002; 359: 1393-1401.
8. Brandt L, Feino Cunha J, Weinreich Olsen A, et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun 2002; 70: 672-678.
9. Behr MA, Wilson MA, Gill WP, et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999; 284: 1520-1523.
10. Behr MA. BCG-different strains, different vaccines? Lancet Infect Dis 2002; 2: 86-92.
11. Ohara N, Yamada T. Recombinant BCG vaccines. Vaccine 2001; 19: 4089-4098.
12. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001; 19: 93-129.
13. Caminero JA, Pena MJ, Campos-Herrero MI, et al. Exogenous reinfection with tuberculosis on a European island with a moderate incidence of disease. Am J Respir Crit Care Med 2001; 163: 717-720.
14. Vuola JM, Ristola MA, Cole B, et al. Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial. AIDS 2003; 17: 2351-2355.
15. Clark-Curtiss JE, Haydel SE. Molecular genetics of Mycobacterium tuberculosis pathogenesis. Annu Rev Microbiol 2003; 57: 517-549.
16. Kaufmann SH. Is the development of a new tuberculosis vaccine possible? Nat Med 2000; 6: 955-960.
17. Andersen P. TB vaccines: progress and problems. Trends Immunol 2001; 22: 160-168.
18. Huygen K, Content J, Denis O, et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 1996; 2: 893-898.
19. Weinrich Olsen A, van Pinxteren LA, Meng Okkels L, Birk Rasmussen P, Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect Immun 2001; 69: 2773-2778.
20. Reed SG, Alderson MR, Dalemans W, Lobet Y, Skeiky YA. Prospects for a better vaccine against tuberculosis. Tuberculosis (Edinb) 2003; 83: 213-219.
21. Britton WJ, Palendira U. Improving vaccines against tuberculosis. Immunol Cell Biol 2003; 81: 34-45.
22. Olsen AW, Hansen PR, Holm A, Andersen P. Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen. Eur J Immunol 2000; 30: 1724-1732.
23. Skeiky YA, Alderson MR, Ovendale PJ, et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 2004; 172: 7618-7628.
24. Brooks JV, Frank AA, Keen MA, Bellisle JT, Orme IM. Boosting vaccine for tuberculosis. Infect Immun 2001; 69: 2714-2717.
25. Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, Hill AV. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 2003; 171: 1602-1609.
26. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci U S A 2000; 97: 13853-13858.
27. Horwitz MA, Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect Immun 2003; 71: 1672-1679.
28. Pym AS, Brodin P, Majlessi L, et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 2003; 9: 533-539.
29. Hess J, Miko D, Catic A, Lehmensiek V, Russell DG, Kaufmann SH. Mycobacterium bovis Bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes. Proc Natl Acad Sci U S A 1998; 95: 5299-5304.
30. Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-544.
31. Camacho LR, Ensergueix D, Perez E, Gicquel B, Guilhot C. Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis. Mol Microbiol 1999; 34: 257-267.
32. Perez E, Samper S, Bordas Y, Guilhot C, Gicquel B, Martin C. An essential role for phoP in Mycobacterium tuberculosis virulence. Mol Microbiol 2001; 41: 179-187.
33. Smith DA, Parish T, Stoker NG, Bancroft GJ. Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect Immun 2001; 69: 1142-1150.
34. Sampson SL, Dascher CC, Sambandamurthy VK, et al. Protection elicited by a double leucine and pantothenate auxotroph of Mycobacterium tuberculosis in guinea pigs. Infect Immun 2004; 72: 3031-3037.
35. Corbel MJ, Fruth U, Griffiths E, Knezevic I. Report on a WHO consultation on the characterisation of BCG strains, Imperial College, London 15-16 December 2003. Vaccine 2004; 22: 2675-2680.
36. Orme IM, McMurray DN, Belisle JT. Tuberculosis vaccine development: recent progress. Trends Microbiol 2001; 9: 115-118.
37. McShane H, Pathan AA, Sander CR, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004; 10: 1240-1244.
38. Young DB. Building a better tuberculosis vaccine. Nat Med 2003; 9: 503-504.